New copycat cancer drug tested against original
NCT ID NCT06587451
Summary
This study tested a new, potentially lower-cost version (biosimilar) of an existing melanoma drug called nivolumab (Opdivo). It compared how the body processes the drugs, their effectiveness, and safety when combined with another drug (ipilimumab/Yervoy) in adults with advanced skin cancer that cannot be removed by surgery or has spread. The goal was to see if the new version works the same as the original.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sandoz Investigational Site
Santiago, Chile
-
Sandoz Investigational Site
Athens, Greece
-
Sandoz Investigational Site
Thessaloniki, Greece
-
Sandoz Investigational Site
Pisa, Italy
-
Sandoz Investigational Site
Vilnius, Lithuania
-
Sandoz Investigational Site
Kuala Lumpur, Malaysia
-
Sandoz Investigational Site
Pulau Pinang, Malaysia
-
Sandoz Investigational Site
Putrajaya, Malaysia
-
Sandoz Investigational Site
Bacolod, Philippines
-
Sandoz Investigational Site
Warsaw, Poland
-
Sandoz Investigational Site
Lisbon, Portugal
-
Sandoz Investigational Site
Daejeon, South Korea
-
Sandoz Investigational Site
Málaga, Spain
-
Sandoz Investigational Site
Oviedo, Spain
-
Sandoz Investigational Site
Santander, Spain
-
Sandoz Investigational Site
Santiago de Compostela, Spain
-
Sandoz Investigational Site 1
Santiago, Chile
-
Sandoz Investigational Site 1
Busan, South Korea
-
Sandoz Investigational Site 2
Tbilisi, Georgia
-
Sandoz Investigational Site 2
Seoul, South Korea
-
Sandoz Investigational Site 2
Madrid, Spain
-
Sandoz Investigational Site 2
Valencia, Spain
Conditions
Explore the condition pages connected to this study.